Related references
Note: Only part of the references are listed.Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
Detecting the JAK2 V617F mutation in fresh and 'historic' blood and bone marrow
S. Gattenlohner et al.
LEUKEMIA (2007)
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients
N. Gangat et al.
LEUKEMIA (2007)
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML):: biologic and clinical features
Brunangelo Falini et al.
BLOOD (2007)
Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias
Thomas Illmer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification
Laura Pasqualucci et al.
BLOOD (2006)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders
M. Di Ianni et al.
LEUKEMIA (2006)
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia
Brunangelo Falini et al.
BLOOD (2006)
C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders
Jonathan S. C. Caudill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
